Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia.
5th Department of Internal Medicine-Oncology/Hematology, Krankenhaus Hietzing, Wolkersbergenstraße 1, 1130, Vienna, Austria.
Sophie
S
Pöchlauer
Eva
E
Jäger
Ulrich
U
Jäger
Klaus
K
Geissler
D051940:B7-2 Antigen / Q000096:biosynthesis; D015536:Down-Regulation; D004341:Drug Evaluation; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009113:Muramidase / Q000097:blood; D009363:Neoplasm Proteins / Q000097:blood; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D014407:Tumor Cells, Cultured
D051940:B7-2 Antigen; C508609:IL10 protein, human; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D016753:Interleukin-10; D009113:Muramidase